Legal Opinion

Merck Sharp & Dohme Corp. v. Albrecht

Supreme Court of the United States

Decided May 20, 2019No. 17-290PublishedCited by 107 opinions

1Opinion of the CourtJustice Breyer

*1672When Congress enacted the Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040, as amended, 21 U.S.C. § 301 et seq. , it charged the Food and Drug Administration with ensuring that prescription drugs are "safe for use under the conditions prescribed, recommended, or suggested" in the drug's "labeling." § 355(d). When the FDA exercises this authority, it makes careful judgments about what warnings should appear on a drug's label for the safety of consumers.

For that reason, we have previously held that "clear evidence" that the FDA would not have approved a change to the drug's label…

2Cases cited14 opinions

  1. MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
  2. Miller v. FentonSupreme Court of the United States · 1985
  3. Wyeth v. LevineSupreme Court of the United States · 2009
  4. Teva Pharm. United States, Inc. v. Sandoz, Inc.Supreme Court of the United States · 2015
  5. Barnett Bank of Marion County, N. A. v. NelsonSupreme Court of the United States · 1996

9 more not listed; retrieve them via the Exa API.

3Cited by107 opinions

  1. Kansas v. GarciaSupreme Court of the United States · 2020
  2. Virginia Uranium, Inc. v. WarrenSupreme Court of the United States · 2019
  3. Wilkinson v. GarlandSupreme Court of the United States · 2024
  4. Barbara Kaiser v. Johnson & JohnsonCourt of Appeals for the Seventh Circuit · 2020
  5. Edwin Hardeman v. Monsanto CompanyCourt of Appeals for the Ninth Circuit · 2021

102 more not listed; retrieve them via the Exa API.

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API